When did Anaptysbio Inc file this 8-K?

Anaptysbio Inc (ANAB) filed this Current Report (Form 8-K) with the SEC on August 11, 2026. The accession number assigned by EDGAR is 0001193125-26-344583.

What does an 8-K disclose?

Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).

What is the key takeaway from this filing?

Stockholders elected two Class III directors and approved auditor, executive compensation, and equity plan amendment. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.

What Item codes does an 8-K cover?

An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.

Where can I find Anaptysbio Inc's prior current reports on EDGAR?

The SEC EDGAR browser lists every 8-K Anaptysbio Inc has filed under CIK 1370053, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Boardroom Alpha

ANAB · Current Report (Form 8-K) · Filed August 11, 2026

Anaptysbio Inc — Current Report (Form 8-K)

Form

8-K

Filed

August 11, 2026

Period

Aug 11, 2026

Ticker

ANAB

Accession

0001193125-26-344583

Anaptysbio Inc on Boardroom Alpha View on SEC EDGAR

Boardroom Alpha · Filing insights

Stockholders elected two Class III directors and approved auditor, executive compensation, and equity plan amendment.

About Anaptysbio Inc

Market cap

$1.6B

1Y TSR

+266.8%

3Y TSR

+62.3%

Board grade

Sector

Healthcare

CEO

Daniel Faga

Last annual meeting: Aug 11, 2026 · View full Anaptysbio Inc profile →

8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2026

ANAPTYSBIO, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-37985	20-3828755
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

10770 Wateridge Circle, Suite 210
San Diego, California		92121
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 858 362-6295

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	ANAB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 11, 2026, AnaptysBio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders and the following proposals were adopted:

Election of two Class III directors, Hollings Renton and John P. Schmid, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders or until such time as his respective successor has been duly elected and qualified or until such director’s earlier resignation or removal:



Nominees	Shares For	Shares Withheld / Abstaining	Broker Non-Votes
Hollings Renton	15,304,522	6,613,642	2,084,465
John P. Schmid	20,314,669	1,603,495	2,084,465

Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2027:



Shares For	Shares Against	Shares Withheld/Abstaining	Broker Non-Votes
22,343,352	1,640,401	18,876	-

Non-binding, advisory approval of compensation paid to the Company’s named executive officers:



Shares For	Shares Against	Shares Withheld/Abstaining	Broker Non-Votes
21,274,791	609,979	33,394	2,084,465

Approval of the amendment to the Company’s 2017 Equity Incentive Plan:



Shares For	Shares Against	Shares Withheld/Abstaining	Broker Non-Votes
15,563,882	6,332,813	21,469	2,084,465

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



10.1			Amendment No. 1 to AnaptysBio, Inc. Amended and Restated 2017 Equity Incentive Plan.
104			Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			ANAPTYSBIO, INC.

Date:	August 11, 2026	By:	/s/ Christopher M. Murphy
			Christopher M. Murphy Chief Financial Officer

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

See Filings Intelligence Schedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Anaptysbio Inc (ANAB)

8-KCurrent Report
Sep 21, 2026
8-KCurrent Report
Jul 30, 2026
DEFA14AAdditional Proxy Materials
Jun 29, 2026
DEF 14AProxy Statement
Jun 29, 2026
8-KCurrent Report
Jun 22, 2026
8-KCurrent Report
May 29, 2026
8-KCurrent Report
May 21, 2026
10-QQuarterly Report
May 12, 2026
8-KCurrent Report
May 12, 2026
8-KCurrent Report
May 11, 2026
10-K/AAmended Annual Report
Apr 28, 2026
8-K/AAmended Current Report
Apr 24, 2026

Continue researching

Reference

Frequently asked questions

When did Anaptysbio Inc file this 8-K?: Anaptysbio Inc (ANAB) filed this Current Report (Form 8-K) with the SEC on August 11, 2026. The accession number assigned by EDGAR is 0001193125-26-344583.
What does an 8-K disclose?: Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?: Stockholders elected two Class III directors and approved auditor, executive compensation, and equity plan amendment. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?: An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Anaptysbio Inc's prior current reports on EDGAR?: The SEC EDGAR browser lists every 8-K Anaptysbio Inc has filed under CIK 1370053, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer